Abstract
Purpose
BRCA1-associated protein (BRAP) was first identified by its ability to bind to the nuclear localization signalling motif of BRCA1 and other proteins. Subsequently, human BRAP has been found to exert multiple functions, many of which are related to cancer development. Up till now, however, the role of BRAP in glioma development has remained obscure. Here, we report a role for BRAP in mediating the proliferation and migration of glioma cells both in vitro and in vivo.
Methods
The expression of BRAP in 98 glioma patient samples was determined by immunohistochemistry, after which associations between BRAP expression and patient prognosis were assessed. A short hairpin RNA (shRNA) was used to knock down BRAP and an expression vector was used to exogenously overexpress BRAP in glioma cells. The effects of BRAP expression on tumour cell behaviour in vitro and in an in vivo xenograft mouse model were examined.
Results
We found that in glioma patients BRAP expression was associated with a favourable prognosis. We also found that shRNA-mediated knockdown of BRAP facilitated the proliferation and migration of glioma cells and the self-renewal of glioma stem cells. In parallel, we found that BRAP knockdown increased tumour growth and invasion and decreased survival in an in vivo glioma xenograft mouse model. Mechanistically, we found that BRAP inhibited glioma cell proliferation and migration, as well as glioma stem cell self-renewal via the TGF-β/PI3K/AKT/mTOR signalling pathway.
Conclusions
Together, our findings identify BRAP as a mediator of glioma cell proliferation, migration and glioma stem cell self-renewal.
Similar content being viewed by others
References
K.A. McNeill, Epidemiology of brain tumors. Neurol Clin 34, 981–998 (2016)
Q.T. Ostrom, H. Gittleman, L. Stetson, S. Virk, J.S. Barnholtz-Sloan, Epidemiology of intracranial Gliomas. Prog Neurol 30, 1–11 (2018)
R. Stupp, M. Brada, M.J. van den Bent, J.C. Tonn, G. Pentheroudakis, High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl 3), iii93–ii101 (2014)
D. Matias, J. Balca-Silva, L.G. Dubois, B. Pontes, V.P. Ferrer, L. Rosario, A. do Carmo, J. Echevarria-Lima, A.B. Sarmento-Ribeiro, M.C. Lopes, V. Moura-Neto, Dual treatment with shikonin and temozolomide reduces glioblastoma tumor growth, migration and glial-to-mesenchymal transition. Cell Oncol 40, 247–261 (2017)
J.I. Bastien, K.A. McNeill, H.A. Fine, Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date. Cancer 121, 502–516 (2015)
S. Li, C.Y. Ku, A.A. Farmer, Y.S. Cong, C.F. Chen, W.H. Lee, Identification of a novel cytoplasmic protein that specifically binds to nuclear localization signal motifs. J Biol Chem 273, 6183–6189 (1998)
C. Chen, R.E. Lewis, M.A. White, IMP modulates KSR1-dependent multivalent complex formation to specify ERK1/2 pathway activation and response thresholds. J Biol Chem 283, 12789–12796 (2008)
S.D. Hayes, H. Liu, E. MacDonald, C.M. Sanderson, J.M. Coulson, M.J. Clague, S. Urbe, Direct and indirect control of mitogen-activated protein kinase pathway-associated components, BRAP/IMP E3 ubiquitin ligase and CRAF/RAF1 kinase, by the deubiquitylating enzyme USP15. J Biol Chem 287, 43007–43018 (2012)
S.A. Matheny, C. Chen, R.L. Kortum, G.L. Razidlo, R.E. Lewis, M.A. White, Ras regulates assembly of mitogenic signalling complexes through the effector protein IMP. Nature 427, 256–260 (2004)
S.A. Matheny, M.A. White, Ras-sensitive IMP modulation of the Raf/MEK/ERK cascade through KSR1. Methods Enzymol 407, 237–247 (2006)
S.A. Matheny, M.A. White, Signaling threshold regulation by the Ras effector IMP. J Biol Chem 284, 11007–11011 (2009)
S. Shoji, K. Hanada, N. Ohsawa, M. Shirouzu, Central catalytic domain of BRAP (RNF52) recognizes the types of ubiquitin chains and utilizes oligoubiquitin for ubiquitylation. Biochem J 474, 3207–3226 (2017)
J. Czyzyk, H.C. Chen, K. Bottomly, R.A. Flavell, p21 Ras/impedes mitogenic signal propagation regulates cytokine production and migration in CD4 T cells. J Biol Chem 283, 23004–23015 (2008)
R.G. Davies, K.M. Wagstaff, E.A. McLaughlin, K.L. Loveland, D.A. Jans, The BRCA1-binding protein BRAP2 can act as a cytoplasmic retention factor for nuclear and nuclear envelope-localizing testicular proteins. Biochim Biophys Acta 1833, 3436–3444 (2013)
M. Asada, K. Ohmi, D. Delia, S. Enosawa, S. Suzuki, A. Yuo, H. Suzuki, S. Mizutani, Brap2 functions as a cytoplasmic retention protein for p21 during monocyte differentiation. Mol Cell Biol 24, 8236–8243 (2004)
A.J. Fulcher, D.M. Roth, S. Fatima, G. Alvisi, D.A. Jans, The BRCA-1 binding protein BRAP2 is a novel, negative regulator of nuclear import of viral proteins, dependent on phosphorylation flanking the nuclear localization signal. FASEB J 24, 1454–1466 (2010)
K. Ozaki, H. Sato, K. Inoue, T. Tsunoda, Y. Sakata, H. Mizuno, T.H. Lin, Y. Miyamoto, A. Aoki, Y. Onouchi, S.H. Sheu, S. Ikegawa, K. Odashiro, M. Nobuyoshi, S.H. Juo, M. Hori, Y. Nakamura, T. Tanaka, SNPs in BRAP associated with risk of myocardial infarction in Asian populations. Nat Genet 41, 329–333 (2009)
L. Wu, B. Xi, D. Hou, X. Zhao, J. Liu, H. Cheng, Y. Shen, X. Wang, J. Mi, The single nucleotide polymorphisms in BRAP decrease the risk of metabolic syndrome in a Chinese young adult population. Diab Vasc Dis Res 10, 202–207 (2013)
Y.C. Liao, Y.S. Wang, Y.C. Guo, K. Ozaki, T. Tanaka, H.F. Lin, M.H. Chang, K.C. Chen, M.L. Yu, S.H. Sheu, S.H. Juo, BRAP activates inflammatory cascades and increases the risk for carotid atherosclerosis. Mol Med 17, 1065–1074 (2011)
F. Zhang, C. Liu, Y. Xu, G. Qi, G. Yuan, Z. Cheng, J. Wang, G. Wang, Z. Wang, W. Zhu, Z. Zhou, X. Zhao, L. Tian, C. Jin, J. Yuan, G. Zhang, Y. Chen, L. Wang, T. Lu, H. Yan, Y. Ruan, W. Yue, D. Zhang, A two-stage association study suggests BRAP as a susceptibility gene for schizophrenia. PLoS One 9, e86037 (2014)
J.W. Kim, Y.M. Choe, J.G. Shin, B.L. Park, H.D. Shin, I.G. Choi, B.C. Lee, Associations of BRAP polymorphisms with the risk of alcohol dependence and scores on the alcohol use disorders identification test. Neuropsychiatr Dis Treat 15, 83–94 (2019)
Y. Zhao, L. Wei, M. Shao, X. Huang, J. Chang, J. Zheng, J. Chu, Q. Cui, L. Peng, Y. Luo, W. Tan, W. Tan, D. Lin, C. Wu, BRCA1-Associated Protein Increases Invasiveness of Esophageal Squamous Cell Carcinoma. Gastroenterology 153, 1304–1319 e1305 (2017)
J. Tang, S. Xi, G. Wang, B. Wang, S. Yan, Y. Wu, Y. Sang, W. Wu, R. Zhang, T. Kang, Prognostic significance of BRCA1-associated protein 1 in colorectal cancer. Med Oncol 30, 541 (2013)
F.R. Schumacher, S.L. Schmit, S. Jiao, C.K. Edlund, H. Wang, B. Zhang, L. Hsu, S.C. Huang, C.P. Fischer, J.F. Harju, G.E. Idos, F. Lejbkowicz, F.J. Manion, K. McDonnell, C.E. McNeil, M. Melas, H.S. Rennert, W. Shi, D.C. Thomas, D.J. Van Den Berg, C.M. Hutter, A.K. Aragaki, K. Butterbach, B.J. Caan, C.S. Carlson, S.J. Chanock, K.R. Curtis, C.S. Fuchs, M. Gala, E.L. Giovannucc, S.M. Gogarten, R.B. Hayes, B. Henderson, D.J. Hunter, R.D. Jackson, L.N. Kolonel, C. Kooperberg, S. Kury, A. LaCroix, C.C. Laurie, C.A. Laurie, M. Lemire, D. Levine, J. Ma, K.W. Makar, C. Qu, D. Taverna, C.M. Ulrich, K. Wu, S. Kono, D.W. West, S.I. Berndt, S. Bezieau, H. Brenner, P.T. Campbell, A.T. Chan, J. Chang-Claude, G.A. Coetzee, D.V. Conti, D. Duggan, J.C. Figueiredo, B.K. Fortini, S.J. Gallinger, W.J. Gauderman, G. Giles, R. Green, R. Haile, T.A. Harrison, M. Hoffmeister, J.L. Hopper, T.J. Hudson, E. Jacobs, M. Iwasaki, S.H. Jee, M. Jenkins, W.H. Jia, A. Joshi, L. Li, N.M. Lindor, K. Matsuo, V. Moreno, B. Mukherjee, P.A. Newcomb, J.D. Potter, L. Raskin, G. Rennert, S. Rosse, G. Severi, R.E. Schoen, D. Seminara, X.O. Shu, M.L. Slattery, S. Tsugane, E. White, Y.B. Xiang, B.W. Zanke, W. Zheng, L. Le Marchand, G. Casey, S.B. Gruber, U. Peters, Genome-wide association study of colorectal cancer identifies six new susceptibility loci. Nat Commun 6, 7138 (2015)
R.J. Gilbertson, J.N. Rich, Making a tumour's bed: Glioblastoma stem cells and the vascular niche. Nat Rev Cancer 7, 733–736 (2007)
J. Marjanovic Vicentic, D. Drakulic, I. Garcia, V. Vukovic, P. Aldaz, N. Puskas, I. Nikolic, G. Tasic, S. Raicevic, L. Garros-Regulez, N. Sampron, M.J. Atkinson, N. Anastasov, A. Matheu, M. Stevanovic, SOX3 can promote the malignant behavior of glioblastoma cells. Cell Oncol 42, 41–54 (2019)
L.M. Nusblat, M.J. Carroll, C.M. Roth, Crosstalk between M2 macrophages and glioma stem cells. Cell Oncol 40, 471–482 (2017)
C.D. Stiles, D.H. Rowitch, Glioma stem cells: a midterm exam. Neuron 58, 832–846 (2008)
I. Pastushenko, C. Blanpain, EMT transition states during tumor progression and metastasis. Trends Cell Biol 29, 212–226 (2019)
T. Brabletz, R. Kalluri, M.A. Nieto, R.A. Weinberg, EMT in cancer. Nat Rev Cancer 18, 128–134 (2018)
L. Zhang, F. Zhou, P. ten Dijke, Signaling interplay between transforming growth factor-beta receptor and PI3K/AKT pathways in cancer. Trends Biochem Sci 38, 612–620 (2013)
D.A. Fruman, C. Rommel, PI3K and cancer: Lessons, challenges and opportunities. Nat Rev Drug Discov 13, 140–156 (2014)
R. Grant, L. Kolb, J. Moliterno, Molecular and genetic pathways in gliomas: The future of personalized therapeutics. CNS Oncology 3, 123–136 (2014)
B. Markman, F. Atzori, J. Perez-Garcia, J. Tabernero, J. Baselga, Status of PI3K inhibition and biomarker development in cancer therapeutics. Ann Oncol 21, 683–691 (2010)
J. Polivka Jr., F. Janku, Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol Ther 142, 164–175 (2014)
L.M. Thorpe, H. Yuzugullu, J.J. Zhao, PI3K in cancer: Divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer 15, 7–24 (2015)
Funding
This work was supported by an Open Project of the State Key Laboratory of Medicinal Chemical Biology, Nankai University [grant number 2018048], Fundamental Research Funds for the Central Universities, Nankai University [grant number 63191106], the Chinese National Natural Science Foundation [grant number 81671380, 81902477], Key Project of Tianjin National Natural Science Foundation [grant number 17JCZDJC35900], the Science and Technology Development Foundation of Henan Province [172102310103], Henan Provincial Medical Science and Technology Project [grant number 2018020480] and the Chinese National Natural Science Foundation [grant number 81573737].
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors have no conflict of interest.
Ethics approval and consent to participate
All subjects provided written informed consent before they participated in the study. The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Ethics Committee of Tianjin Huanhu Hospital (NO.2019–14). All human tissue samples were obtained with patient consent. Animal experiments were performed according to the Health guidelines of the Tianjin Huanhu Hospital Animal Use and Care Committee.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Wang, B., Cao, C., Liu, X. et al. BRCA1-associated protein inhibits glioma cell proliferation and migration and glioma stem cell self-renewal via the TGF-β/PI3K/AKT/mTOR signalling pathway. Cell Oncol. 43, 223–235 (2020). https://doi.org/10.1007/s13402-019-00482-8
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13402-019-00482-8